drugset / Trial / NCT00002461

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma

NCT00002461

RandomizedParallel-groupTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. Bone marrow or peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy to kill more cancer cells. PURPOSE: This phase II trial is studying giving high-dose chemotherapy followed by bone marrow or peripheral stem cell transplantation to see how well it works in treating patients with refractory Hodgkin's disease or non-Hodgkin's lymphoma.

Timeline

Start
1988-04
Primary completion
1991-07
Completion
1991-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 200 mg/m2 Intravenous
Subject Cyclophosphamide Other / unclassified Intravenous
Subject Etoposide Small molecule 2400 mg/m2 Intravenous
Subject Etoposide Small molecule 3000 mg/m2 Intravenous
Subject carmustine Small molecule 600 mg/m2 Intravenous
Subject carmustine Small molecule 1050 mg/m2 Intravenous
Subject filgrastim Protein / enzyme biologic Subcutaneous
Subject sargramostim Protein / enzyme biologic Subcutaneous

Indications